Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

Cassava Sciences announced that the phase 3 trial of its Alzheimer's drug, simufilam, did not meet its primary endpoints.

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are ...

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

Cassava Sciences (SAVA) stock faces uncertainty after a major late-stage trial setback for the company's Alzheimer's candiate ...

Momentum investors will watch Tesla (TSLA) today. The stock, which broke out from the $200 - $250 range last month to close ...

The company's future now appears to be in flux, as simufilam was its only drug in clinical trials, The New York Times reported. Also: a Roche lung cancer drug has failed to improve survival; pharma ...

Opinion writers tackle these public health issues.